PCSK9 In The Spotlight Ahead Of AHA Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Publication of full Phase II results for Sanofi/Regeneron’s SRA236553 in the New England Journal of Medicine put the focus on the PCSK9 class days ahead of the annual AHA meeting, where Amgen and Pfizer will be presenting new data for rival drugs.
You may also be interested in...
Regeneron/Sanofi’s PSCK9 Inhibitor Might Need Two-Week Dosing Schedule
Fully human antibody for hypercholesterolemia is set to enter Phase III next month, and while the firms aren’t discussing the protocol, recent data suggest that REGN727/SRA236553 may need dosing every two weeks, rather than the more convenient monthly schedule.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.